Core Insights - The company is transitioning from a device-placement model to a utilization-focused model to unlock the economic potential of its global installed base of over 36,000 units [1] - A 'medtech' approach is being adopted, shifting from relationship-driven sales to a value-based selling model that emphasizes clinical economic differentiation and ROI for providers [1] Performance Summary - Q4 performance was positively impacted by a favorable mix shift towards consumables, which grew by 1.7% year-over-year, leading to significant operating leverage and margin expansion [1] - Adjusted EBITDA for Q4 reached $15 million, indicating approximately 700 basis points of margin expansion despite a slight revenue decline [1] Market Trends - The aesthetics market is evolving into a lifestyle category that emphasizes prevention and routine care, benefiting HydraFacial's non-invasive and repeatable treatment profile [1] Strategic Initiatives - The 'utilization flywheel' is identified as the core strategy, where brand demand drives traffic, increasing device usage and high-margin consumables revenue [1] - The company is reactivating underleveraged assets like SkinStylus in the microneedling category to enhance its role as a comprehensive skin health platform [1]

Core Insights - The Beauty Health Company is positioned for long-term growth in the professional skin health market, leveraging its established brand and technology to enhance commercial execution and operational discipline [1][5][24]. Financial Performance - In Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, with consumables revenue increasing to $57.7 million, up 1.7% from the previous year [11][29]. - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [11]. - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4%, driven by a favorable shift towards consumables revenue [12][30]. - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [12][31]. - For the full year 2025, net sales totaled $300.8 million, down from $334.3 million in 2024, with adjusted EBITDA increasing to $45.1 million from $12.3 million [27]. Market Trends - The U.S. medspa market has expanded significantly, growing from approximately 1,600 locations in 2010 to over 13,000 today, indicating strong consumer interest in skin health [6]. - Consumers are increasingly investing in skin health as a lifestyle choice, seeking clinically proven outcomes and natural results [6][9]. - The market is shifting towards combination therapies and clinically validated results, favoring companies with strong provider education and recurring revenue models [15][16]. Strategic Initiatives - The company aims to enhance its commercial model by focusing on device utilization rather than just placement, which is expected to drive long-term growth [10][14]. - Key priorities include improving salesforce excellence, marketing discipline, and focused innovation to strengthen the installed base and expand the role of HydraFacial in provider practices [17][20][22]. - The company plans to launch a next-generation HydraFacial system by 2028, aimed at enhancing the value proposition for providers [57]. Guidance and Outlook - For 2026, the company expects revenue to be in the range of $285 million to $305 million, with positive adjusted EBITDA of $35 million to $45 million, reflecting a focus on execution and stabilization [32][33]. - The first quarter of 2026 is projected to have revenue of $63 million to $68 million, typically the lowest revenue quarter due to seasonal dynamics [35]. - The company anticipates returning to growth in 2027 as operational changes take effect and innovation scales [34][37].

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, marking a significant margin expansion [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with adjusted EBITDA increasing to $45.1 million from $12.3 million [21][22] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in the global install base [12] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [12] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [7][8] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][18] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the demand for non-invasive treatments, despite macroeconomic pressures affecting capital equipment sales [12][39] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [25][28] - The company expects to return to growth in 2027 as operational changes take effect [19][28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 in a stronger position than the previous year [20] - The average spend per treatment in the U.S. for consumables is up 10% year-over-year, driven by premium boosters [62] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results; the aesthetics category has faced pressure due to credit tightness [38][39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year; marketing strategies are being adjusted to target new demographics [46][49] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [55] Question: Consumables performance and pricing strategy - A 5% price increase on consumables was well-received, and the company is evaluating overall pricing strategy moving forward [76]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [21] Business Line Data and Key Metrics Changes - The installed base of systems reached over 36,000 globally, with more than 1,000 devices placed in Q4 [12] - The capital equipment segment continues to face pressure, consistent with broader macroeconomic conditions [10] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers [7] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][17] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [12] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [19][25] - The company expects to return to growth in 2027 as operational changes take effect [28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 as a stronger entity [20] - Adjusted EBITDA for the full year increased significantly to $45.1 million from $12.3 million in the prior year [21] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points [37] - The medical segment continues to grow, driven by med spas using HydraFacial to attract patients [39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year [44] - The company is addressing the needs of new demographics entering the category, focusing on outcome-driven protocols [47] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [53] Question: Pricing strategy and consumable utilization - A 5% price increase on consumables was well-received, with no significant complaints [73] - Providers who understand how to prescribe boosters use them three times more than those who do not [74]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [9][21] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [9] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [9] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [10][22] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [10][23] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [20] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in its global install base [11] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [11] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [6] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [6][7] Company Strategy and Development Direction - The company aims to shift its model from device placement to device utilization, focusing on unlocking the economic potential of its installed base [8] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [12][14] - The company plans to enhance its product ecosystem and strengthen its market position through disciplined innovation and targeted marketing efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [11] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half as execution initiatives take hold [17][24] - The company expects to return to growth in 2027, driven by operational changes and innovation [17][26] Other Important Information - The company ended 2025 with approximately $232.7 million in cash equivalents, a decrease from $370.1 million in 2024, primarily due to debt restructuring [21] - The company is focusing on improving its balance sheet and financial discipline, which has contributed to its stabilization [10][18] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D for future innovation [30][31] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points, impacting procedure volume and device placements [36][37] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with a focus on restructuring sales and customer service teams to better support smaller accounts [41][43] - The company is addressing the needs of new demographics, including men and Gen Z, by positioning HydraFacial as a lifestyle routine [45][46] Question: New system launch timeline and additional services - The next-generation HydraFacial is in early development, with a planned launch in 2028, aimed at providing compelling reasons for upgrades [51][52] Question: Consumables performance and pricing strategy - The company successfully implemented a 5% price increase on consumables without significant pushback, and is evaluating overall pricing strategy moving forward [74]

Core Viewpoint - The article discusses the best bear market stocks to buy, emphasizing the importance of defensive stocks that outperform the market during economic downturns [1][2]. Defensive Stocks - Defensive stocks are characterized by their ability to provide protection against economic unpredictability, often coming from sectors like utilities, healthcare, and consumer staples [1]. - Michael Wilson from Morgan Stanley advocates for a shift towards conservative stocks amid economic downturns and tariff concerns, suggesting that quality and defensive equities will continue to outperform [2]. Methodology - The selection process involved using a stock analysis screener to identify consumer defensive stocks with a price target upside of less than 15%, resulting in a ranked list of 13 stocks based on hedge fund holdings as of Q2 2025 [5][6]. Company Highlights - **Beyond Meat, Inc. (NASDAQ:BYND)**: Reported a 19.6% year-over-year decline in Q2 revenue to $75 million and a net loss of $29.2 million. The company plans to cut 6% of its workforce and focus on margin expansion and streamlined distribution [8]. It introduced a new plant-based product, Beyond Ground, and aims to innovate with lentil sausages and chickpea hot dogs [9]. - **BRF S.A. (NYSE:BRFS)**: Merged with Marfrig Global Foods, creating MBRF Global Foods Company S.A. The merger aims to generate BRL 805 million ($141 million) in annual synergies. Despite challenges, BRF reported 3% revenue growth in Q2 2025 to BRL 15.4 billion, with significant growth in its pet food and plant-based segments [11][12]. The company is positioned for stronger global growth post-merger [13]. - **The Beauty Health Company (NASDAQ:SKIN)**: Reported Q2 2025 revenue of $78.2 million and EPS of $0.03, exceeding expectations. The company focuses on provider engagement and innovation, launching initiatives to enhance product development and brand loyalty [15][16]. It plans to expand its consumable product lines and has clarified asset rights to reduce risk for creditors [17].